Nagasaki H, Shinagawa K
Kurume University School of Medicine, Department of Ophthalmology, Fukuoka, Japan.
Curr Opin Ophthalmol. 1995 Jun;6(3):70-5. doi: 10.1097/00055735-199506000-00012.
Despite the recent progress in vitreous surgery, treatment of proliferative vitreoretinopathy (PVR) is still difficult. Even if the reattachment of the retina is successful, visual prognosis is often unsatisfactory. Identification of clinical risk factors for PVR provides useful guidelines for planning the management of rhegmatogeneous retinal detachment. This review summarized the current concept for pathogenesis, clinical risk factors, and medical treatment for PVR. The presence of retinal breaks and the breakdown of the blood-retinal barrier are prerequisite to development of PVR. Almost all risk factors for PVR are associated with intravitreal dispersion of retinal pigment epithelial cells or the breakdown of the blood-retinal barrier.
尽管玻璃体手术最近取得了进展，但增生性玻璃体视网膜病变（PVR）的治疗仍然困难。即使视网膜复位成功，视觉预后往往也不尽人意。识别PVR的临床危险因素为孔源性视网膜脱离的治疗管理规划提供了有用的指导方针。这篇综述总结了PVR发病机制、临床危险因素和药物治疗的当前概念。视网膜裂孔的存在和血视网膜屏障的破坏是PVR发生的先决条件。几乎所有PVR的危险因素都与视网膜色素上皮细胞的玻璃体内扩散或血视网膜屏障的破坏有关。
